Thu, December 22, 2022
Wed, December 21, 2022
Tue, December 20, 2022

Matthew Barcus Initiated (XLO) at Strong Buy and Held Target at $7 on, Dec 21st, 2022

Matthew Barcus of Chardan Capital, Initiated "Xilio Therapeutics, Inc." (XLO) at Strong Buy and Held Target at $7 on, Dec 21st, 2022.

Matthew has made no other calls on XLO in the last 4 months.



There is 1 other peer that has a rating on XLO. Out of the 1 peers that are also analyzing XLO, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Dane Leone of "Raymond James" Maintained at Buy with Decreased Target to $13 on, Thursday, November 10th, 2022